December 2016
-
One day after the FDA announced that it has approved Mylan’s ANDA for Wixela Inhub, a generic version of Advair Diskus fluticasone propionate/salmeterol DPI, Mylan has announced that it will launch the product by the… Read more . . .
-
Canadian cannabinoid developer Tetra Bio-Pharma says that it has filed a patent application covering technology related to its PPP001 cannabis drug pellet. According to the company, the patent application covers fabrication methods and composition of matter.… Read more . . .
-
The FDA announced that it has approved Mylan’s generic version of Advair Diskus fluticasone propionate/salmeterol DPI for the treatment of asthma in patients four years old and older and for the treatment of COPD. Three… Read more . . .
-
Aradigm Corporation, which submitted an MAA for its dual release inhaled ciprofloxacin for the treatment of chronic P. aeruginosa lung infections in non-cystic fibrosis bronchiectasis (NCFBE) patients in March 2018, has announced that it submitted… Read more . . .
-
Novus Therapeutics has provided an update on ongoing Phase 1 clinical trials of its OP0201 nasal MDI for the treatment of otitis media and has announced plans for a Phase 2a study in infants and… Read more . . .
-
Device company Nemera has announced the promotion of the leader of its Innovation Center, Dimitri Grasswill, to VP of Innovation. Grasswill has directed the Innovation Center, located in La Verpillière, France, since 2013. In a… Read more . . .
-
The FDA has approved Promius Pharma’s Tosymra sumatriptan nasal spray (formerly known as DFN-02) for the treatment of migraine, Promius parent company Dr. Reddy’s has announced. The company submitted an NDA for the nasal spray… Read more . . .
-
CDMO Hovione has announced that it issued a $50 million bond, arranged and subscribed by Banco BPI, that is set to mature in 2033 in order to finance an expansion of its production capacity. The company has… Read more . . .
-
Circassia Pharmaceuticals will pay AIT Therapeutics $7.35 million up front plus potential milestone payments and royalties for the exclusive rights to commercialize AIT’s AirNOvent ventilator compatible nitric oxide in the US and China, the company… Read more . . .
-
Ziccum, a spin out from Inhalation Sciences, has announced that it submitted a patent application for a temperature-stable dry powder formulation of adenovirus. According to the company, the formulation, which would be suitable for delivery… Read more . . .
Featured event:
5th Annual Inhaled & Nasal Biologics | DNA Forum
5th Annual Inhaled & Nasal Biologics | DNA Forum
24th-25th September 2026, Cambridge, UK
Join us for a ground-breaking and insightful forum: Two days of cutting-edge talks and networking opportunities in this complex area of drug and vaccine development.
With renowned industry leaders who will share their insights and real-world case studies, our speakers will explore innovative formulation and delivery technologies and the rationale behind overcoming development challenges. Don’t miss out on this opportunity to learn more about key topics shaping the future of inhaled therapeutics.
Get online to see speakers announced so far. Registration is live – save your seat now!
Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
October 14-October 15: Advancing Bioequivalence Frameworks for Inhalation and Nasal Drug Products: Optimizing In Vitro, In Vivo, and In Silico Methods, Rockville, MD, USA
October 19-October 20: MVIC Autumn Training 2026, Lund, Sweden
October 21-October 22: MVIC Symposium, Lund, Sweden
November 10-November 11: Rescon Europe 2026, Porto, Portugal
December 9-December 11: DDL 2026, Edinburgh, Scotland